<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367646">
  <stage>Registered</stage>
  <submitdate>18/12/2014</submitdate>
  <approvaldate>21/01/2015</approvaldate>
  <actrnumber>ACTRN12615000042549</actrnumber>
  <trial_identification>
    <studytitle>Detection of Individuals with Preclinical, Prodromal and Mild Alzheimer's Disease for Therapeutic Trials.
</studytitle>
    <scientifictitle>Detection of Individuals with Preclinical, Prodromal and Mild Alzheimer's Disease optimizing the use of cognitive and blood biomarker findings to increase the rate of amyloid scan positive subjects using Amyloid and Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging for Therapeutic trials.</scientifictitle>
    <utrn />
    <trialacronym>NIL</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Preclinical Alzheimer's Disease</healthcondition>
    <healthcondition>Prodromal Alzheimer's Disease</healthcondition>
    <healthcondition>Mild Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cognitive assessment will be performed at visits one and four lasting approximately one hour.
Blood biomarker sampling will occur at visit 4. 
The Amyloid PET scan will be done at visit two and involves intravenous injection of 200 +/-10%MBq of (18F)Nav4694. A 20-minute scan will be acquired starting at 50 minutes post injection.  Where MRI Brain scan results with a 3D sequence from within the past six months are not available, an MRI will be done at visit 2 or visit 3.  An FDG PET scan will be done at visit three using an intravenous injection of 185 +/-10% of (18F)FDG.  A 15-minute scan will be acquired starting at 30 minutes post injection.</interventions>
    <comparator>Amyloid imaging will be compared to MRI and FDG PET imaging.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Early detection / Screening</interventioncode>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Early detection of Alzheimer's Disease through use of  Amyloid and FDG PET scans, and blood biomarkers, in conjunction with other standard imaging, neuropsychological and medical assessments.</outcome>
      <timepoint>Following completion of imaging, cognitive assessment and blood biomarker testing.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Develop a register of subjects with a diagnosis of Preclinical, Prodromal or Mild Alzheimer's Disease who wish to be contacted when therapeutics trials become available. </outcome>
      <timepoint>Following completion of investigative procedures and discussion with the subject and their usual medical practitioner,  therapeutic trials will be offered when they become available.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>MMSE &gt; 20 and &lt;29.
&gt; 6 years of education.
English speaking.
Adequate visual/auditory acuity for cognitive testing.
Interest in participating in Therapeutic Trials.</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Other neurodegenerative disorders, severe mental illnesses.  History of cancer within the last 5 years (excluding skin or insitu prostate cancer).
Drug and alcohol abuse.
MRI contraindications.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Subjects are enrolled following Specialist confirmation of Preclinical, Prodromal or Mild Alzheimer's disease.
They attend a screening visit for Study discussion and Informed Consent. They are then assessed according to the inclusion and exclusion criteria and are enrolled in the study if eligible.
</concealment>
    <sequence>Nonrandomised</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>17/12/2014</anticipatedstartdate>
    <actualstartdate>17/12/2014</actualstartdate>
    <anticipatedenddate>17/06/2016</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <postcode>3084 - Heidelberg</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Chris Rowe</primarysponsorname>
    <primarysponsoraddress>Austin Health
145 Studley Road
Heidelberg, Victoria
Australia 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC Grant APP1071430</fundingname>
      <fundingaddress>NHMRC
National Health and Medical Research Council 
GHD Building Level 1, 
16 Marcus Clarke Street, 
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Investigator Sponsored Study through a Clinical Trial Research Agreement with AstraZeneca Pharmaceuticals LP.</fundingname>
      <fundingaddress>141 Portland Street, 10th Floor, Cambridge, MA 02139.</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to use recent advances in PET scanning techniques, in particular Amyloid scanning to assist in the detection of Preclinical, Prodromal and Mild Alzheimer's disease. 
</summary>
    <trialwebsite>www.florey.edu.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics </ethicname>
      <ethicaddress>Austin Health
145 Studley Rd,
Heidelberg, Victoria
Australia  3084</ethicaddress>
      <ethicapprovaldate>12/09/2014</ethicapprovaldate>
      <hrec>HREC/14/Austin/325</hrec>
      <ethicsubmitdate>17/07/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Chris Rowe</name>
      <address>Austin Health
145 Studley Rd
Heidelberg, Victoria
Australia  3084</address>
      <phone>+61 03 9496 5000</phone>
      <fax />
      <email>chris.rowe@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Cheryl Donohue</name>
      <address>The Florey Institute of Neuroscience and Mental Health
155 Oak St
Parkville, Victoria
Australia  3052</address>
      <phone>+61 03 9389 2938</phone>
      <fax>+61 03 9387 5061</fax>
      <email>cheryl.donohue@florey.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Chris Rowe</name>
      <address>Austin Health
145 Studley Rd
Heidelberg, Victoria
Australia  3084</address>
      <phone>+61 03 9496 5000</phone>
      <fax />
      <email>chris.rowe@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Cheryl Donohue</name>
      <address>The Florey Institute of Neuroscience and Mental Health
155 Oak St
Parkville 
Victoria  3052</address>
      <phone>+61 03 9389 2938</phone>
      <fax>+61 03 9387 5061</fax>
      <email>cheryl.donohue@florey.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>